The four indicators with the highest reported frequency in safety evaluation for coronary heart disease patients were as follows: elevated ALT/aspartate aminotransferase, myalgia, rhabdomyolysis, and myopathy. This evidence concerns the gene GPT and rhabdomyolysis.